LifeMD, Inc.(LFMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,315 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in LFMD
Events flagged as statistical outliers against LFMD's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-05
LFMD quality score dropped 15 points (40→25) on a new filing
View source filing →
LFMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for LifeMD, Inc. (LFMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFMD at 35.2/100 on a 32-signal composite quality model, placing it at rank #2,315 of 2,962 stocks — the bottom half of the AI-ranked universe. LFMD scores in the top quartile across institutional flow (89.0). Areas of concern include earnings quality (1.3) and free cash flow (19.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LifeMD, Inc. reports quarterly revenue of $47.3M, net income of $-7.1M, free cash flow of $-7.0M. Top institutional holders of LFMD by reported 13-F value include BlackRock, FEDERATED HERMES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LFMD trades on the Nasdaq exchange and files with the SEC under CIK 948320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LifeMD, Inc. directly from SEC EDGAR. LifeMD, Inc.'s 13F Pro composite quality score has ranged between 23 and 54 since 2021, currently 35.2 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.
Revenue
Q2 2026
$47.3M
Net Income
Q2 2026
$-7.1M
Free Cash Flow
Q2 2026
$-7.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+25.3% YoYNet Income
+167.0% YoYOperating Income
+62.4% YoYEPS (Diluted)
+141.7% YoYTotal Assets
-7.5% YoYOp. Cash Flow
-52.7% YoYFree Cash Flow
-60.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $194.1M +25.3% | $154.8M +1.5% | $152.5M +28.2% | $119.0M +28.2% | $92.9M +149.0% | $37.3M |
| Net Income | $14.4M +167.0% | $-21.4M -3.9% | $-20.6M +54.8% | $-45.5M +25.2% | $-60.9M -3.8% | $-58.6M |
| Operating Income | $-7.7M +62.4% | $-20.4M -40.8% | $-14.5M +66.7% | $-43.4M +20.0% | $-54.3M +6.1% | $-57.8M |
| EPS (Diluted) | $0.25 +141.7% | $-0.60 | — | — | — | — |
| Total Assets | $70.4M -7.5% | $76.1M +30.1% | $58.5M +127.9% | $25.7M -48.6% | $49.9M +282.4% | $13.1M |
| Operating Cash Flow | $8.3M -52.7% | $17.5M +98.6% | $8.8M +138.5% | $-22.9M +30.7% | $-33.1M -172.7% | $-12.1M |
| Free Cash Flow | $6.4M -60.1% | $16.0M +86.3% | $8.6M +137.0% | $-23.3M +30.1% | $-33.3M | — |
Get alerted when LFMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LifeMD, Inc. including:
Top Institutional Holders of LFMD
BlackRock, Inc.
$12.5M3,034,535 shFEDERATED HERMES, INC.
$11.3M2,747,655 shVANGUARD CAPITAL MANAGEMENT LLC
$7.2M1,734,756 shSTATE STREET CORP
$5.4M1,318,784 shRENAISSANCE TECHNOLOGIES LLC
$4.5M1,079,525 shGEODE CAPITAL MANAGEMENT, LLC
$4.4M1,067,698 shPRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
$3.7M897,224 shBRC Group Holdings, Inc.
$2.6M637,319 shROYCE & ASSOCIATES LP
$2.6M636,124 shAQR CAPITAL MANAGEMENT LLC
$2.6M619,506 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $12.5M | 3,034,535 |
| FEDERATED HERMES, INC. | $11.3M | 2,747,655 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.2M | 1,734,756 |
| STATE STREET CORP | $5.4M | 1,318,784 |
| RENAISSANCE TECHNOLOGIES LLC | $4.5M | 1,079,525 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.4M | 1,067,698 |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | $3.7M | 897,224 |
| BRC Group Holdings, Inc. | $2.6M | 637,319 |
| ROYCE & ASSOCIATES LP | $2.6M | 636,124 |
| AQR CAPITAL MANAGEMENT LLC | $2.6M | 619,506 |
Companies Similar to LFMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Inogen Inc
MARAVAI LIFESCIENCES HOLDINGS, INC.
Orthofix Medical Inc.
RxSight, Inc.
Alpha Teknova, Inc.
USANA HEALTH SCIENCES INC
Maze Therapeutics, Inc.
SI-BONE, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LFMD on your watchlist
Track score changes the day LifeMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LFMD a good stock to buy?
13F Pro's AI-powered analysis of LifeMD, Inc. (LFMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFMD are available on the LFMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LFMD is classified as a small company.
Which hedge funds own LFMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LifeMD, Inc.'s investment landscape.